FAQ: Aditxt's Pearsanta Subsidiary Begins Clinical Study for Blood-Based Endometriosis Test
Summary
Aditxt's subsidiary Pearsanta has initiated enrollment in a clinical study for the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. This study aims to validate a non-invasive alternative to the current gold standard laparoscopic diagnosis, potentially enabling earlier and more accurate detection of the condition.
What is the main announcement in this content?
Aditxt’s subsidiary Pearsanta has begun enrollment in a clinical study for the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET’s performance to laparoscopic diagnosis across up to 1,000 participants referred for surgery.
Why is this clinical study significant?
This study supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. It represents a potential improvement over the current gold standard of laparoscopic diagnosis, which is more invasive.
How does the new test compare to current diagnostic methods?
The MET test is a blood-based diagnostic being compared to laparoscopic diagnosis, which is the current gold standard for endometriosis detection. The blood test offers a non-invasive alternative to surgical diagnosis.
Who is conducting this clinical study?
The study is being conducted by Pearsanta Inc., a subsidiary of Aditxt Inc. (NASDAQ: ADTX). The first enrollment site is Dedicated to Women OB/GYN in Dover, Delaware.
Where is the clinical study taking place?
The first enrollment site is Dedicated to Women OB/GYN in Dover, Delaware. The study will involve up to 1,000 participants referred for surgery.
What is Aditxt’s role in healthcare innovation?
Aditxt is a social innovation platform accelerating promising health innovations through its ecosystem of research institutions, industry partners, and shareholders. The company operates four programs focused on autoimmunity, cancer and early diseases detection, infectious diseases and women’s health.
How can investors get more information about Aditxt?
The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX. To view the full press release about this study, visit https://ibn.fm/WiIhM.
What are the potential benefits of this blood-based test?
The MET test could provide earlier and more accurate detection of endometriosis through a non-invasive blood test. This represents a significant advancement over the current surgical diagnostic approach, potentially improving patient experience and outcomes.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 265902